- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00622414
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors
A Phase I Study of VEGF Trap (NSC# 724770, IND# 100137) in Children With Refractory Solid Tumors
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To estimate the maximum tolerated dose (MTD) or recommended phase II dose (RPTD) of aflibercept administered intravenously every 14 days in children with relapsed or refractory solid tumors.
II. To estimate the MTD or RPTD of aflibercept administered intravenously every 21 days in these patients.
III. To define and describe the toxicities of intravenous aflibercept administered on a 14-day and 21-day schedule, respectively.
IV. To characterize the pharmacokinetics of intravenous aflibercept in these patients.
SECONDARY OBJECTIVES:
I. To define, preliminarily, the antitumor activity of intravenous aflibercept within the confines of a phase I study.
OUTLINE: This is a multicenter study.
PART 1: Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for 2 years in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive aflibercept until the maximum tolerated dose (MTD) is determined.
PART 2: Patients receive aflibercept as in part 1 at 150% of the MTD determined in part 1. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
Blood samples are collected prior to treatment on day 1 of courses 1, 2, and 5 or 6 for pharmacokinetic studies.
After completion of study treatment, patients are followed for at least 30 days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Lurie Children's Hospital-Chicago
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed malignancy at original diagnosis or relapse (excluding intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of serum alpha-fetoprotein of beta-HCG)
- Patients with recurrent or refractory solid tumors are eligible, including primary CNS tumors or patients with known CNS metastases
- Current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
- Measurable or evaluable disease
- No evidence of CNS hemorrhage on baseline MRI for patients with known CNS disease
Karnofsky performance status (PS) 50-100% (for patients > 10 years of age) or Lansky PS 50-100% (for patients ≤ 10 years of age)
- Neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 1 week prior to study entry
- Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
Patients with solid tumors without bone marrow involvement must meet the following criteria:
- ANC ≥ 1,000/mm³
- Platelet count ≥ 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)
- Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)
- Negative protein dipstick OR urine protein < 500 mg by 24-hour urine collection
Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine based on age/gender as follows:
- 0.6 mg/dL for male and female patients 1 to < 2 years of age
- 0.8 mg/dL for male and female patients 2 to < 6 years of age
- 1.0 mg/dL for male and female patients 6 to < 10 years of age
- 1.2 mg/dL for male and female patients 10 to < 13 years of age
- 1.5 mg/dL (male) or 1.4 mg/dL (female) for patients 13 to < 16 years of age
- 1.7 mg/dL (male) or 1.4 mg/dL (female) for patients ≥ 16 years of age
- Bilirubin ≤ 1.5 times upper limit of normal (U.N.) for age
- SEPT (ALT) ≤ 110 μ/L (approx. 2.5 times U.N.) (for the purpose of this study, the U.N. for SEPT is 45 μ/L)
- Serum albumin ≥ 2 g/dL
- PT/aPTT < 1.2 times U.N.
- Patients must have a diastolic blood pressure ≤ the 95th percentile for age and gender and not be receiving treatment for hypertension
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No evidence of active graft-vs-host disease
- No uncontrolled infection
- No serious or nonhealing wound, ulcer, or bone fracture
- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to day 1 of study treatment
No clinically significant cardiovascular disease within the past 6 months, including any of the following:
- History of cerebrovascular accident
- New York Heart Association class III-IV congestive heart failure
- Serious cardiac arrhythmia requiring medication
- Unstable angina pectoris
- Pulmonary embolism
- Deep vein thrombosis
- Other thromboembolic events
- No evidence of a current bleeding diathesis or coagulopathy
- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in the study
- No significant traumatic injury within 4 weeks prior to day 1 of study treatment
- Must be able to comply with the safety monitoring requirements of the study in the opinion of the investigator
- Recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
- No prior aflibercept
- At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)
- At least 6 weeks since prior monoclonal antibodies
- At least 2 weeks since prior local palliative radiotherapy (small port)
- At least 6 weeks since other prior substantial bone marrow radiotherapy
- At least 2 months since prior stem cell transplantation or rescue
- At least 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis
- At least 4 weeks since prior major surgical procedure, laparoscopic procedure, or open biopsy and no anticipation of need for major surgical procedures during the course of the study
- At least 48 hours since prior fine needle aspirate, central line placement, or subcutaneous port placement
- At least 1 week since prior core biopsy
- At least 1 week since prior and no concurrent hematopoietic growth factors
- At least 1 week since prior and no concurrent biologic agents
- At least 1 week since prior and no concurrent dexamethasone
- No concurrent antihypertensive medications for blood pressure control
- No concurrent anti-thrombotic or anti-platelet agents (e.g., warfarin [Coumadin ®],heparin, low molecular weight heparin, aspirin, and/or ibuprofen, or other NSAIDs)
- No concurrent medications known to inhibit platelet function or known to selectively inhibit cyclooxygenase-2 activity (e.g., all antipyretic and anti-inflammatory medications except acetaminophen)
- No other concurrent anticancer therapy, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy
- No other concurrent investigational drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (ziv-aflibercept)
PART 1: Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for 2 years in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive aflibercept until the maximum tolerated dose (MTD) is determined. PART 2: Patients receive aflibercept as in part 1 at 150% of the MTD determined in part 1. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. |
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose, defined as the maximum dose at which fewer than one-third of patients experience DLT during the initial 2 courses of therapy, graded according to NCI CTCAE version 3.0
Time Frame: Up to 28 days
|
Up to 28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julie Park, COG Phase I Consortium
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2009-01062 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U01CA097452 (U.S. NIH Grant/Contract)
- COG-ADVL0714
- CDR0000584050
- NCI-08-C-0179
- NCI-P08401
- ADVL0714 (Other Identifier: CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Childhood Solid Tumor, Protocol Specific
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt UniversityNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedSirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
Children's Cancer and Leukaemia GroupUnknownUnspecified Childhood Solid Tumor, Protocol SpecificIreland, United Kingdom
Clinical Trials on ziv-aflibercept
-
Regeneron PharmaceuticalsSanofiCompletedSolid TumorsUnited States, Canada
-
Shahid Beheshti University of Medical SciencesUnknownDiabetic Macular EdemaIran, Islamic Republic of
-
Regeneron PharmaceuticalsNational Cancer Institute (NCI)CompletedLymphoma | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Regeneron PharmaceuticalsNational Cancer Institute (NCI)Completed
-
Regeneron PharmaceuticalsNational Cancer Institute (NCI)Completed
-
Dana-Farber Cancer InstituteCompleted
-
Regeneron PharmaceuticalsNational Cancer Institute (NCI)CompletedLymphoma | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
SanofiRegeneron PharmaceuticalsCompletedOvarian Neoplasms | AscitesUnited States, Canada, Spain, India, Belgium, Austria, Hungary, Israel, United Kingdom
-
SanofiRegeneron PharmaceuticalsCompletedNeoplasms | Cancer of the OvaryUnited States, France, Canada, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland
-
SanofiRegeneron PharmaceuticalsCompletedOvarian NeoplasmsUnited States, Italy, Sweden